Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity by unknown
RESEARCH ARTICLE Open Access
Calprotectin and TNF trough serum levels
identify power Doppler ultrasound synovitis
in rheumatoid arthritis and psoriatic
arthritis patients in remission or with low
disease activity
José Inciarte-Mundo1, Julio Ramirez1, Maria Victoria Hernández1, Virginia Ruiz-Esquide1, Andrea Cuervo1,
Sonia Raquel Cabrera-Villalba1, Mariona Pascal2, Jordi Yagüe2, Juan D. Cañete1 and Raimon Sanmarti1*
Abstract
Background: Serum levels of calprotectin, a major S100 leucocyte protein, are associated with disease activity in
rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients. Higher drug trough serum levels are associated with
good response in patients treated with tumour necrosis factor inhibitors (TNFi). Power Doppler ultrasound (PDUS)
synovitis is predictive of flare and progression of structural damage in patients in clinical remission. The purpose of
this study was to analyse the accuracy of calprotectin and TNFi trough serum levels in detecting PDUS synovitis in
RA and PsA patients in clinical remission or with low disease activity who were receiving TNFi.
Methods: We conducted a cross-sectional study of 92 patients (42 with RA, 50 with PsA) receiving adalimumab
(ADA), etanercept (ETN) or infliximab who were in remission or had low disease activity (28-joint Disease Activity
Score based on erythrocyte sedimentation rate <3.2). Associations of calprotectin, TNFi trough serum levels and
acute phase reactants with PDUS synovitis were assessed using correlation and linear regression analyses. The
accuracy and discriminatory capacity in detecting PDUS synovitis was assessed using ROC curves.
Results: PDUS synovitis was found in 62.4 % of RA patients and 32 % of PsA patients. Both RA and PsA patients
with PDUS synovitis had higher calprotectin levels and lower TNFi trough serum levels. Calprotectin positively
correlated with ultrasound scores (all r coefficients >0.50 in RA). Calprotectin correlated with the PDUS synovitis
score in patients treated with ADA and ETN. Using PDUS synovitis (yes or no) as the reference variable, calprotectin
had an AUC of 0.826. The best cut-off was ≥1.66 μg/ml, with a likelihood ratio of 2.77. C-reactive protein (AUC
0.673) and erythrocyte sedimentation rate (AUC 0.731) had a lower discriminatory capacity. TNFi trough serum
levels were significantly associated with PDUS synovitis (OR 0.67, 95 % CI 0.52–0.85, p < 0.001) but their accuracy
(AUC <0.5) was less than that of calprotectin. TNFi trough serum levels were inversely correlated with calprotectin
and PDUS synovitis in RA and PsA patients receiving ADA and ETN.
Conclusions: Calprotectin and TNFi trough serum levels may help identify PDUS synovitis in RA and PsA patients in
clinical remission or with low disease activity.
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arthritis
* Correspondence: sanmarti@clinic.cat
1Department of Rheumatology, Hospital Clinic, University of Barcelona, Carrer
Villarroel 170, 08036 Barcelona, Spain
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Inciarte-Mundo et al. Arthritis Research & Therapy  (2016) 18:160 
DOI 10.1186/s13075-016-1032-z
Background
New therapeutic strategies, including early therapy, treat-
to-target approaches and biological therapies, have led to
substantial improvements in the prognosis of patients
with rheumatoid arthritis (RA) and other types of in-
flammatory arthritis, such as ankylosing spondylitis and
psoriatic arthritis (PsA) [1]. These strategies have enabled
patients to reach clinical remission (i.e., the absence of
clinically detectable joint inflammation), which is now a
realistic therapeutic goal in clinical practice [2]. However,
there is no consensus on what constitutes clinical remis-
sion and which indices should be used to measure it, and
therefore rates of clinical remission depend on the articu-
lar index used. Furthermore, most patients in clinical re-
mission have evidence of inflammatory activity, especially
when less stringent criteria are used [3–6].
Musculoskeletal ultrasound (MSUS), a non-invasive
diagnostic technique, is widely used in rheumatology to
measure joint inflammation with greater sensitivity [7].
Power Doppler (PD) detects synovial flow, a sign of in-
creased synovial vascularization, and better reflects ac-
tive synovial inflammation compared with synovial
hypertrophy (SH) [8]. PD correlates with disease activity
and decreases after treatment, and it is therefore sensi-
tive to change [9–11]. MSUS has revealed that a signifi-
cant proportion of patients classified as being in clinical
remission exhibit power Doppler ultrasound (PDUS)
synovitis, which may explain the joint damage progres-
sion observed in some patients despite no clinical find-
ings of disease activity. In addition, PDUS synovitis is
predictive of clinical flares [12–15].
In rheumatology, promising biomarkers that more ac-
curately reflect the clinical status, including remission,
of patients with inflammatory arthritis have been recog-
nized. Use of these biomarkers might enhance clinical
practice and guide therapeutic decisions. Recently,
serum calprotectin, a heterodimeric complex of two
S100 calcium-binding myeloid-related proteins (MRP8
[or S100A8] and MRP14 [or S100A9]), has been re-
ported to be a sensitive biomarker of disease activity in
patients with RA and patients with spondyloarthritis
[16]. Calprotectin is an important proinflammatory fac-
tor of innate immunity, acting as endogenous damage-
associated molecular pattern molecules via Toll-like
receptor 4 activation [17]. Higher calprotectin levels
have been found in the synovial fluid and serum of RA
and PsA patients [18]. Serum calprotectin levels correl-
ate with disease activity and are independently associ-
ated with radiographic progression in RA [19–21].
Levels decrease significantly after treatment with tumour
necrosis factor inhibitors (TNFi) and might be useful in
monitoring biological therapy [22, 23].
Recent studies have found a significant dose-response
relationship between the extent of clinical improvement
and TNFi trough serum levels [24, 25], with higher drug
trough serum levels being associated with good re-
sponses due to significant decreases in disease activity
[26], less progression of joint damage [27] and reduc-
tions in acute phase response proteins such as C-
reactive protein (CRP) [28].
The aim of this study was to analyse the accuracy of
calprotectin serum levels and TNFi trough serum levels
in detecting PDUS synovitis in RA and PsA patients in
clinical remission or with low disease activity who were
receiving TNFi.
Methods
This cross-sectional study included consecutive RA
(American College of Rheumatology 1987 criteria) and
polyarticular PsA (CASPAR, ClASsification criteria for
Psoriatic Arthritis) patients from our arthritis unit. All
patients were in remission (28-joint Disease Activity
Score based on erythrocyte sedimentation rate [DAS28-
ESR] ≤2.6) or had low disease activity (DAS28-ESR ≤3.2)
in two consecutive visits ≥3 months apart and had been
taking adalimumab (ADA), etanercept (ETN) or inflixi-
mab (IFX) for ≥3 months. Patients with DAS28-ESR
>3.2 or PsA patients with axial or entheseal involvement
or an oligoarticular peripheral pattern were excluded.
Information collected comprised demographic data,
disease duration, autoantibody status, radiological data,
concomitant conventional synthetic disease-modifying
anti-rheumatic drug (csDMARD) therapy, and dose and
duration of biological therapy. Some patients were re-
ceiving reduced-dose biological therapy due to persistent
remission and/or low disease activity. A reduced dose
was defined as treatment with a Lower amount of the
drug or longer interval of administration than recom-
mended in each product package insert.
Measurement of disease activity
Before MSUS assessment, all patients underwent a clinical
assessment including 28-joint swollen and tender joint
counts as well as physician and patient global assessments
with visual analogue scales (0–100 mm). Three composite
disease activity indices were subsequently calculated:
DAS28-ESR [29, 30], Simple Disease Activity Index [31]
and Clinical Disease Activity Index [32].
Ultrasound assessment
Sonographic assessments were carried out using high-
sensitivity ultrasound equipment (MyLab Twice®; Esaote,
Genoa, Italy), with a frequency range from 10 to
14 MHz and a pulse repetition frequency between 500
and 800 Hz. Receiver gain settings were controlled to
eliminate artefacts. Joint MSUS findings were defined ac-
cording to published Outcome Measures in Rheumatoid
Arthritis Clinical Trials (OMERACT) definitions [33]. A
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single experienced sonographer (JR) who was blinded to
the results of the clinical joint examination evaluated 11
joints and tendons of each hand (including proximal in-
terphalangeal joints, metacarpophalangeal joints, and
wrists) for both SH and intra-articular PD signalling
according to European League Against Rheumatism
guidelines [34]. SH and PD signals were graded using a
four-grade semi-quantitative scoring system (0 = no, 1 =
mild, 2 =moderate and 3 = severe) according the meth-
odology of Szkudlarek et al [35]. Intra-rater agreement
on MSUS assessment, calculated as previously described
[36], were 0.83 for SH and 0.90 for PD.
By summing the scores for elementary lesions in each
joint, we calculated the PD score (sum of PD scores in
all joints, range 0–66), the SH score (sum of SH scores
in all joints, range 0–66) and the global score (sum of
the PD and SH scores, range 0–132). PDUS synovitis
was defined as a PD signal in synovial tissue [37]. A
more stringent definition of active synovitis (ultrasound-
defined active synovitis [UdAS]) developed by our group
(SH grade ≥2 plus PDUS synovitis signal) was also re-
corded. UdAS patients showed significantly higher
serum levels of several angiogenic factors thought to be
relevant to RA pathogenesis. Clinically, UdAS-positive
patients showed greater disease activity on the basis of
composite indices different from those used for UdAS-
negative patients [36].
Measurement of serum calprotectin levels, acute phase
response and TNFi trough serum levels
Blood samples were collected immediately before the
next administration of TNFi, centrifuged 20 minutes
after sample collection to separate serum and plasma,
and stored at −80 °C until analysis. Calprotectin serum
levels were determined using an enzyme-linked im-
munosorbent assay (ELISA) test kit (CALPROLAB
Calprotectin ELISA (ALP); Calpro AS, Lysaker, Norway)
in accordance with the manufacturer’s protocol. Briefly,
100 ml of each standard, control and diluted 1:20 sample
in duplicate wells were incubated at room temperature
for 40 minutes. Three washings were done, 100 ml of
the conjugated enzyme were added, and the plates were
incubated at room temperature for 40 minutes. After
three washes and the addition of the enzyme substrate,
the optical density values at 405 nm were determined
using an ELISA reader. To reduce variation in calprotec-
tin determination, the whole procedure was performed
in a Triturus® autoanalyzer (Diagnostic Grifols, Barcelona,
Spain) [38]. ESR was measured using the Westergren
method (Normal Value (NV) <20 mm/h), and CRP
was measured by nephelometry (lowest detection limit
0.01 mg/dl, NV <0.8 mg/dl). Trough serum levels of ETN,
ADA and IFX were measured by using a bridging ELISA
(Promonitor®; Progenika Biopharma, Derio, Spain) that
has been validated and shows adequate correlation in
measuring drug levels and anti-drug antibodies [39].
The study was conducted in accordance with the
Declaration of Helsinki and was approved by the
Hospital Clinic of Barcelona Clinical Research Ethics
Committee (Reg. 2013/8382). Signed informed consent
was obtained from all patients before study enrolment.
Statistical analysis
Continuous data were presented as medians and ranges,
and categorical variables were presented as absolute fre-
quencies and percentages. Groups were compared using
Student’s t test or the Mann-Whitney U test when ap-
propriate. Correlations were assessed using Spearman’s
correlation coefficient. Logistic regression models were
used to assess associations between calprotectin, TNFi
trough serum levels and PDUS synovitis, using ultra-
sound (US) as the dependent variable and calprotectin
and TNFi trough serum levels as independent factors.
Crude ORs with 95 % CIs were calculated. Multivariate
models were constructed to analyse the effect of covari-
ates and to fully adjust the association between calpro-
tectin, TNFi trough serum levels and PDUS synovitis.
Models were fitted separately and compared using the
Akaike information criterion and the Bayesian informa-
tion criterion. The discriminatory capacity of calprotec-
tin, TNFi trough serum levels, CRP and ESR, with PDUS
synovitis (yes or no) as the gold standard, was analysed
using ROC curves, and the best cut-off in terms of sensi-
tivity and specificity was identified. The predictive
values, accuracy and positive likelihood ratio were calcu-
lated. The AUC was estimated using Hanley’s corrected
confidence intervals. The analyses were carried out using
STATA version 11 software (StataCorp, College Station,
TX, USA).
Results
Ninety-two patients were included (42 RA, 50 PsA), and
their median disease duration was 15 (1–44) years.
Forty-four patients were receiving ETN (22 RA and 22
PsA), 32 were taking ADA (14 RA and 18 PsA) and 16
were receiving IFX (6 RA and 10 PsA). The median bio-
logical treatment duration was 63.4 (12–166) months,
and 42 patients had received a reduced dose of bio-
logical therapy. Seventy-one patients (77.2 %) were in re-
mission, and 21 (22.8 %) had low disease activity. PsA
patients included were younger, had a shorter duration
of biological therapy, and had lower percentages of
csDMARD and steroid use than RA patients (Table 1).
Power Doppler ultrasound synovitis and disease status
Forty-three patients (46.7 %) had PDUS synovitis (27 RA
[64.2 %] and 16 PsA [32 %]), of whom 15 (10 RA
[23.8 %] and 5 PsA [10 %]) met the criteria for UdAS
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(SH grade ≥2 plus PDUS synovitis signal). Patients with
PDUS synovitis were mostly female, had a diagnosis of
RA, were more frequently treated with steroids, and had
a higher percentages of low disease activity according to
all indices assessed (Table 2). Similar results were
obtained when UdAS criteria were applied (data not
shown).
Calprotectin, acute phase reactants and power Doppler
ultrasound synovitis
Patients with PDUS synovitis had higher levels of calpro-
tectin (PDUS-negative [n = 49] 1 μg/ml [0.6–3.7] vs.
PDUS-positive [n = 43] 2.68 μg/ml [0.22–5.5], p < 0.001),
CRP (PDUS-negative [n = 49] 0.07 mg/dl [0.1–0.6] vs.
PDUS-positive [n = 43] 0.20 mg/dl [0.01–1.4], p = 0.005)
and ESR (PDUS-negative [n = 49] 8 mm/h [2–29] vs.
PDUS-positive [n = 43] 13 mm/h [2–43], p < 0.001).
Similar results were obtained when patients were ana-
lysed according to diagnosis (RA vs. PsA), although no
significant differences in CRP levels were observed be-
tween PsA patients with versus without PDUS synovitis
(Table 2).
When a more stringent active synovitis criterion (UdAS)
was applied, calprotectin (UdAS [n = 15] 3.48 μg/ml [0.2–
5.5] vs. non-UdAS [n = 77] 1.47 μg/ml [0.06–4.8], p <
0.001), but not CRP (UdAS [n = 15] 0.11 mg/dl [0.05–0.24]
vs. non-UdAS [n = 77] 0.09 mg/dl [0.07–0.13], p = 0.699) or
ESR (UdAS [n = 15] 12.8 mm/h [8.1–20.1] vs. non-UdAS
[n = 77] 9.6 mm/h [8.3–10.9], p = 0.108) distinguished
patients with UdAS from those without UdAS.
Calprotectin strongly correlated with MSUS scores (all
r coefficients >0.50 in RA patients). A weak correlation
was found between ESR and joint indices and MSUS
scores, while CRP correlated only with the PD score in
RA (Table 3). Calprotectin correlated with the PD score
in patients treated with ADA (ρ = −0.591, p < 0.001) and
ETN (ρ = −0.313, p = 0.039), but not in those treated
with IFX.
The accuracy analysis with PDUS synovitis (yes or no)
as the reference variable showed an AUC of 0.826 (95 %
CI 0.742–0.910) and a cut-off calprotectin level of
1.66 μg/ml (sensitivity 79.1 %, specificity 83.4 %). The
positive likelihood ratio of this calprotectin level for
PDUS synovitis was 2.77; the negative likelihood ratio
Table 1 Patients and disease characteristics
Patient characteristics Total (n = 92) RA (n = 42) PsA (n = 50) p Value
Female sex, n (%) 59 (64.1) 34 (81) 25 (50) 0.158
Age, years, median (range) 58 (30–81) 63.5 (30–81) 54.5 (33–77) <0.001
Body index mass, kg/m2, median (range) 26.4 (18–42) 26.2 (19.2–42) 26.6 (18.3–35) 0.189
Disease duration, years, median (range) 15 (1–44) 15.5 (2–44) 14.5 (1–36) 0.785
Presence of erosions, n (%) 53(57.6) 33 (78.6) 20 (40) 0.012
At least one previous biological treatment, n (%) 28 (27) 11 (26) 14 (28) 0.552
Concomitant csDMARD, n (%) 47 (51.1) 32 (76.2) 15 (30) 0.005
Concomitant steroids, n (%) 15 (16.3) 13 (31) 2 (4) <0.001
Prednisone dose, mg/day, median (range) 2.5 (3–5) 2.5 (3–5) 3.7 (3–5) 0.152
Biological treatment duration, months, median (range) 64.8 (12–166) 83.2 (9–165) 58.3 (7.6–166) 0.017
Reduced dosage,a n (%) 42 (45.7) 12 (28.6) 30 (60) <0.001
Albumin, g/dl, median (range) 42.5 (30–49) 32 (30–49) 47 (30–49) 0.005
CRP, mg/dl, median (range) 0.095 (0.01–1.45) 0.10 (0.01–1.4) 0.09 (0.01–0.6) 0.288
ESR, mm/h, median (range) 10 (2–43) 12.5 (2–43) 8.5 (2–32) 0.004
Calprotectin, μg/ml, median (range) 1.67 (0.06–5.54) 2.16 (0.2–5.5) 1.36 (0.06–4.6) 0.002
SJC, median (range) 0 (0–3) 0 (0–3) 0 (0–2) 0.625
TJC, median (range) 0 (0–2) 0 (0–2) 0 (0–1) 0.788
DAS28-ESR, median (range) 1.96 (1.0–3.2) 2.31 (1.3–3.2) 1.82 (1–3.1) <0.001
Remission based on DAS28-ESR, n (%) 71 (77.2) 27 (64.3) 44 (88) 0.005
Low disease activity based on DAS28-ESR, n (%) 21 (22.8) 15 (35.7) 6 (12) 0.005
CDAI, median (range) 6 (2–11.0) 6 (2–11) 6 (2–8) 0.782
SDAI, median (range) 6 (2–11.1) 6 (2–11) 6 (2–8) 0.005
Abbreviations: CDAI Clinical Disease Activity Index, CRP C-reactive protein, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, DAS28-ESR
28-joint Disease Activity Score based on erythrocyte sedimentation rate, ESR erythrocyte sedimentation rate, PsA psoriatic arthritis, RA rheumatoid arthritis, SDAI
Simple Disease Activity Index, SJC swollen joint count, TJC tender joint count
aTreatment regimen with a lesser amount of the drug or longer interval of administration than those recommended in the package insert for each product
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was 2.29; and these values correctly classified PDUS
synovitis in 85 % of patients (Fig. 1). CRP (AUC 0.673)
and ESR (AUC 0.731) had a lower discriminatory cap-
acity than calprotectin. An accuracy analysis for DAS28-
CRP using PDUS synovitis as the reference variable was
also performed. ROC analysis showed a lower accuracy
than calprotectin, with an AUC of 0.721 (95 % CI 0.612–
0.829, p = 0.005) and a cut-off DAS28-CRP value of 1.61
(sensitivity 72 %, specificity 61 %, positive likelihood ra-
tio 1.85, negative likelihood ratio 0.45), and it correctly
classified PDUS synovitis in 66.3 % of patients.
Adjusted multivariate regression analysis showed a
strong association between calprotectin and PDUS syno-
vitis (OR 4.6, 95 % CI 2.31–9.26, p < 0.001) according to
the different covariates (combined therapy, reduced
dose, use of glucocorticoids, disease duration, and pres-
ence of autoantibodies or erosive disease). Backward se-
lection of variables did not substantially modify the
association between calprotectin and PDUS synovitis
(Table 4). Other variables associated with PDUS syno-
vitis were long-standing disease (OR 1.10, 95 % CI 1.02–
1.18, p < 0.001) and steroid use (OR 18.1, 95 % CI 2.73–
120.2, p < 0.005).
TNFi trough serum levels and power Doppler ultrasound
synovitis
RA patients with PDUS synovitis had significantly lower
ETN, ADA and IFX trough serum levels. PsA patients
with PDUS synovitis had lower trough serum levels of
ETN and ADA but not IFX (Table 2). ADA and ETN,
but not IFX, trough serum levels inversely correlated
with PDUS and MSUS global scores. Similar results were
obtained for UdAS (Table 5).
Although adjusted multivariate regression analysis
showed that lower TNFi trough serum levels were sig-
nificantly associated with PDUS synovitis (OR 0.67, 95 %
CI 0.52–0.85, p < 0.001), TNFi trough serum levels had
low accuracy (AUC <0.5).
Calprotectin and TNFi trough serum levels
Calprotectin inversely correlated with ADA (ρ =−0.461, p=
0.008) and ETN (ρ= −0.436, p = 0.005) trough serum levels,
although non-significant correlations were found for IFX.
Discussion
The results of this study show a significant proportion of
patients with RA and PsA in remission or with low
Table 2 Calprotectin, disease activity, ultrasound assessment and tumour necrosis factor inhibitor trough serum levels according to
diagnosis
Patient characteristics RA (n = 42) PsA (n = 50)
PDUS-negative (n = 15) PDUS-positive (n = 27) PDUS-negative (n = 34) PDUS-positive (n = 16)
Female sex, n (%) 11 (73.3) 23 (85.2) 15 (44.1) 10 (62.5)a
Age, years, median (range) 62 (49–78) 64 (30–81) 53 (33–77) 55 (40–72)
Disease duration, years, median (range) 13 (8–28) 17 (2–44) 13.5 (1–28) 16 (3–36)
Concomitant csDMARD, n (%) 11 (73.3) 21 (77.8) 11 (32.4) 4 (25)
Reduced dose, n (%) 4 (26.7) 8 (29.6) 21 (61.8) 9 (56.3)
Calprotectin, μg/ml, median (range) 1.44 (0.2–2.4) 2.95 (0.2–5.5)a 0.70 (0.06–3.7) 2.36 (0.9–4.6)b
CRP, mg/dl, median (range) 0.07 (0.02–0.1) 0.30 (0.01–1.4)a 0.08 (0.01–0.6) 0.09 (0.01–0.3)
ESR, mm/h, median (range) 10 (2–24) 13 (2–43) 8 (2–29) 13 (4–32)a
SJC, median (range) 0 (0–1) 0 (0–3) 0 (0–1) 0 (0)
TJC, median (range) 0 (0–1) 0 (0–2) 0 (0–1) 0 (0–1)
DAS28-ESR, median (range) 2.08 (1.5–2.6) 2.62 (1.3–3.2)a 1.67 (1–2.7) 2.15 (1.1–3.1)a
Remission based on DAS28-ESR, n (%) 13 (86.7) 14 (51.9)b 9 (90) 6 (75)a
Low disease activity based on DAS28-ESR, n (%) 2 (13.3) 13 (48.1)b 1 (10) 2 (25)
SDAI, median (range) 6.02 (2–8) 6.26 (2–11)a 5.10 (2–8) 6.04 (2–8.3)
CDAI, median (range) 6 (2–8) 6 (2–11) 5 (2–8) 6 (2–8)
ADA trough serum levels, μg/ml, median (range) 8.39 (4.2–12) 1.68 (0.6–12)a 6.95 (4.1–12) 0.88 (0.2–9.8)a
ETN trough serum levels, μg/ml, median (range) 2.54 (0.2–4.7) 0.98 (0.7–2.3)a 1.38 (01–3.5) 0.91 (0.6–1.6)a
IFX trough serum levels, μg/ml, median (range) 8.39 (4.2–12) 1.68 (0.6–12)a 3.21 (0.7–7.7) 2.86 (0.1–6.5)
Abbreviations: ADA adalimumab, CDAI Clinical Disease Activity Index, CRP C-reactive protein, csDMARD conventional synthetic disease-modifying anti-rheumatic
drug, DAS28-ESR 28-joint Disease Activity Score based on erythrocyte sedimentation rate, ESR erythrocyte sedimentation rate, ETN etanercept, IFX infliximab, PDUS
power Doppler ultrasound, PsA psoriatic arthritis, RA rheumatoid arthritis, SDAI Simple Disease Activity Index, SJC swollen joint count, TJC tender joint count
ap < 0.05
bp < 0.001
Inciarte-Mundo et al. Arthritis Research & Therapy  (2016) 18:160 Page 5 of 10
disease activity who were treated with TNFi had PDUS
synovitis, together with significantly higher levels of
serum calprotectin, which was more accurate than acute
phase reactants (APRs) in identifying PDUS synovitis.
Patients with PDUS synovitis had significantly lower
TNFi serum levels, and there was an inverse correlation
between TNFi serum levels and calprotectin in the two
diseases. Therefore, calprotectin and TNFi serum levels
may be considered as sensitive biomarkers of synovial
inflammation in RA and PsA patients in remission or
with low disease activity being treated with TNFi.
Developing standardized instruments to detect synovial
inflammation in RA and PsA patients in remission or with
low disease activity is a clinical challenge. MSUS, a non-
invasive, relatively inexpensive, dynamic technique that al-
lows real-time examination and more sensitive detection
of joint inflammation than clinical examination [7], is suf-
ficiently sensitive to measure changes in disease activity,
thereby permitting the monitoring of therapeutic re-
sponses in patients receiving biological therapy [40].
An increasing amount of data supports the emerging
role and clinical utility of imaging techniques such as
MSUS in evaluating patients with inflammatory arthritis
in clinical remission or with low disease activity. Clinical
remission is known not to be equivalent to the absence
of imaging-detected synovitis in RA. Only one-third of
patients classified as being in clinical remission had a
total absence of painful, swollen or tender joints, regard-
less of the criteria used, and most patients had ongoing
active synovitis on the basis of MSUS [41], which may
explain the continuing structural progression in some
patients despite apparent clinical remission [42].
US-based findings in RA patients in remission should
be interpreted with caution. Patients with grade 1 SH,
especially those without PD, could be considered to have
non-pathologic disease and may be present in the
healthy population [43]. In RA patients, SH could sug-
gest the chronic anatomical changes of earlier synovitis
rather than current synovial inflammation [44]. In con-
trast, the presence of PD has repeatedly demonstrated
greater sensitivity in detecting active synovitis [11, 12,
15, 45]. In our cohort, 64 % of RA patients and 32 % of
PsA patients had PDUS synovitis, although only 24 % of
RA patients and 10 % of PsA patients met the more
stringent criteria of UdAS. We previously demonstrated
that UdAS captured only patients with potentially clinic-
ally relevant symptoms and correlated with increased
serum levels of angiogenic biomarkers [37].
Subjective clinical symptoms, joint examination and
laboratory measurements of APR are not sufficiently
sensitive to exclude ongoing inflammation in patients
with low disease activity levels. TNFi improves the clin-
ical signs of RA while reducing serum levels of CRP and
ESR [46]. The reduction in APRs may be due in part to
Table 3 Correlation between musculoskeletal ultrasound scores
and calprotectin, acute phase reactants and disease activity indices

























Abbreviations: CDAI Clinical Disease Activity Index, CRP C-reactive protein,
DAS28-ESR 28-joint Disease Activity Score based on erythrocyte sedimentation
rate, ESR erythrocyte sedimentation rate, PsA psoriatic arthritis, RA rheumatoid
arthritis, SDAI Simple Disease Activity Index, SH synovial hypertrophy
Data presented are Spearman’s ρ correlations
ap < 0.001
bp < 0.05
Fig. 1 ROC curve fitting calprotectin discriminatory capacity to
detect power Doppler ultrasound synovitis
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the direct systemic effect of TNFi on hepatic synthesis
of CRP and other APRs, such as fibrinogen, rather than
to true improvements in local joint synovitis. In contrast,
calprotectin is released by activated phagocytes such as
synovial monocytes and granulocytes [18], and its levels
reflect local ongoing inflammation rather than a
systemic inflammatory response. We recently demon-
strated that calprotectin better stratifies disease activity
than CRP or ESR in RA patients receiving tocilizumab, a
biological agent with a dramatic impact on APRs due to
its blockage of interleukin 6 [38]. We also found signifi-
cant associations between calprotectin and disease status
in RA and PsA patients treated with TNFi, with calpro-
tectin levels stratifying disease activity more accurately
than CRP and ESR in patients with low levels of inflam-
mation [47].
Calprotectin may be useful in certain groups of pa-
tients seen in daily clinical practice, such as patients with
inflammatory arthralgia, in order to permit an early
diagnosis, or patients with recent-onset RA, in whom
CRP and ESR levels may be normal. Clinical assessment
of RA patients with comorbidities such as fibromyalgia
or osteoarthritis may be challenging; in these patients,
calprotectin could help rule out inflammatory activity
and elucidate the source of pain, guiding therapeutic de-
cisions (e.g., the initiation or tapering of biological treat-
ment). However, at present, according to our results,
one of the most interesting clinical applications may be
its use in patients in remission or with low disease activ-
ity. It is known that the widely used definition of remis-
sion based on DAS28 better represents minimal disease
activity than remission. Therefore, calprotectin could
rule out ongoing inflammation in these patients and
Table 4 Associations between calprotectin, tumour necrosis factor inhibitor trough serum levels and power Doppler ultrasound
synovitis
Unadjusted β coefficient Fully adjusted β coefficient
OR (95 % CI) p Value OR (95 % CI) p Value
Calprotectin, μg/ml 3.22 (1.95–5.33) <0.0001 4.63 (2.31–9.26) <0.0001
TNFi trough serum levels, μg/ml 0.77 (0.65–0.91) 0.002 0.67 (0.52–0.85) 0.001
Age, years 1.03 (0.99–1.06) 0.164
Disease duration, years 1.05 (1.00–1.10) 0.067 1.10 (1.02–1.18) 0.016
ESR, mm/h 1.13 (1.05–1.22) 0.001
Female sex 2.92 (1.18–7.20) 0.020
Combined therapy, yes or no 1.64 (0.72–3.76) 0.245
Disease activity according to DAS28-ESR 0.001
Remission (<2.6) 1
Low disease activity (2.6–3.2) 7.35 (2.23–24.21)




Steroids, yes or no 2.67 (0.83–8.55) 0.099 18.12 (2.73–120.16) 0.003
Monotherapy, yes or no 0.59 (0.26–1.34) 0.206
Constant 0.02 (0.003–0.16) <0.0001
Abbreviations: DAS28-ESR 28-joint Disease Activity Score based on erythrocyte sedimentation rate, ESR erythrocyte sedimentation rate, PsA psoriatic arthritis, RA
rheumatoid arthritis, TNFi tumour necrosis factor inhibitors
Table 5 Correlation between musculoskeletal ultrasound scores
and tumour necrosis factor inhibitor trough serum levels
Total (n = 92) RA (n = 42) PsA (n = 50)
Adalimumab
Doppler score −0.842a −0.898a −0.803a
SH score −0.329 −0.447 −0.107
Global score −0.547b −0.639b −0.423b
Etanercept
Doppler score −0.649a −0.543b −0.791a
SH score −0.024 −0.169 −0.052
Global score −0.504b −0.251 −0.362
Infliximab
Doppler score −0.178 −0.530 −0.076
SH score −0.052 −0.667 −0.122
Global score −0.132 −0.870b −0.060
PsA psoriatic arthritis, RA rheumatoid arthritis, SH synovial hypertrophy
Data presented are Spearman’s ρ correlations
ap < 0.001
bp < 0.05
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prevent residual activity being undertreated, with the as-
sociated therapeutic and prognostic implications.
In only two reports, both about patients with active
RA, have authors analysed the association between cal-
protectin and MSUS. The first included 20 RA patients
starting treatment with ADA [20], and the other com-
prised 37 RA patients taking csDMARDs [48]. Both
studies showed significant associations between calpro-
tectin and MSUS, and the second study suggested that
calprotectin might be superior to APRs in monitoring
US synovitis. To the best of our knowledge, our present
study is the first to include PsA patients and to be fo-
cused on patients in remission or with low disease activ-
ity receiving biological therapy. Our results show that
PsA patients had a lower rate of PDUS synovitis than
RA patients did. Moreover, as observed in RA patients,
PsA patients with PDUS synovitis had significantly
higher calprotectin levels. Calprotectin correlated better
and more consistently with MSUS than APRs, and we
found significant correlations between calprotectin and
PD, SH and US global scores. The US global score com-
bines inflammatory (power Doppler) and structural find-
ings (synovial hypertrophy) in an attempt to capture the
whole state of the joint, although previous studies have
shown that only the PD score was associated with radio-
graphic progression [49]. In light of the strong correl-
ation in our present study, it seems logical that
calprotectin and PDUS synovitis both identify local ac-
tive synovitis in patients with low levels of disease
activity.
This is particularly interesting, considering recent evi-
dence suggesting that TNF blockade depends on the
trough serum levels achieved. It is reported that patients
with a good response to TNFi therapy have higher drug
trough serum levels [24, 25]. Our results show that pa-
tients with PDUS synovitis had lower trough serum
levels. TNFi trough serum levels inversely correlated
with PD in patients receiving ADA and ETN (all r coeffi-
cients >0.50), although they were less accurate than cal-
protectin in detecting PDUS synovitis. In a previous
study, researchers detected no significant influence of
anti-TNF pharmacokinetics on the SH and PD scores in
RA patients, although TNFi trough serum levels were
not measured in that study [50]. Therefore, our study is
the first to be focused on the relationship between TNFi
trough serum levels and MSUS assessment in RA and
PsA patients.
Our study had some limitations. First, this was a
cross-sectional study in patients with long-standing RA
and PsA who were receiving prolonged TNFi therapy,
and therefore the value of calprotectin, TNFi trough
serum levels and PDUS synovitis as prognostic factors
for flares or in monitoring therapeutic responses to bio-
logical therapy was not evaluated. Second, we used
DAS28 ≤ 3.2 as the inclusion criterion. This allowed re-
sidual tender and/or swollen joints in patients classified
as being in remission and did not include the feet. How-
ever, it is the most widely used composite articular
index, and therefore our results would be clinically ap-
plicable. Although the DAS28 was developed to assess
disease activity in RA, studies support its use in PsA pa-
tients receiving biological therapy [30]. Third, concomi-
tant treatment with csDMARDs, steroids and non-
steroidal anti-inflammatory drugs was not standardized,
owing to the observational nature of the study. Finally,
US assessment was performed by only one rheumatolo-
gist, and therefore inter-observer reliability could not be
calculated. This may be a weakness of the study because
of the known significant variability between observers in
the US assessment of synovitis [51].
Conclusions
PsA patients in remission or with low disease activity
had a lower rate of PDUS synovitis than RA patients. Pa-
tients with PDUS synovitis had higher calprotectin levels
and lower TNFi trough serum levels, reflecting local, on-
going synovial inflammation. Calprotectin was more ac-
curate than APRs in detecting PDUS synovitis in these
patients. TNFi trough serum levels inversely correlated
with the PD score and calprotectin levels. Calprotectin
and drug trough serum levels may help clinicians iden-
tify US active synovitis in RA and PsA patients in clinical
remission or with low disease activity treated with TNFi.
Abbreviations
ADA, adalimumab; AIC, Akaike information criterion; APR, acute phase
reactant; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein;
csDMARD, conventional synthetic disease-modifying anti-rheumatic drug;
DAS28-ESR, 28-joint Disease Activity Score based on erythrocyte sedimentation
rate; ELISA, enzyme-linked immunosorbent assay; ESR, erythrocyte sedimentation
rate; ETN, etanercept; IFX, infliximab; MRP, myeloid-related protein; MSUS,
musculoskeletal ultrasound; OMERACT, Outcome Measures in Rheumatoid Arthritis
Clinical Trials; PD, power Doppler; PDUS, power Doppler ultrasound; PsA, psoriatic
arthritis; RA, rheumatoid arthritis; SDAI, Simple Disease Activity Index; SH, synovial
hypertrophy; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour
necrosis factor inhibitors; UdAS, ultrasound-defined active synovitis; US, ultrasound;
NV, normal value
Acknowledgements
The authors acknowledge the statistical assistance provided by Dr. Loreto
Carmona, Dr. María Jesús García de Yébenes y Prous and Miguel Sampayo;
the technical advice of David Buss; and the Spanish Rheumatology Society.
Funding
This work was supported by the Hospital Clinic of Barcelona (grant “Emili
Letang 2013”) and the Catalan Society of Rheumatology (research grant 2013).
Authors’ contributions
RS, JI-M, JR and JY conceived of and designed the study. RS, JI-M, JR, MVH,
SRC-V and VR-E acquired data. RS, JI-M, JR, VR-E, JDC, MP, SRC-V and MVH
analysed and interpreted the data. All authors were involved in drafting the
manuscript or revising it critically for important intellectual content, and all
authors read and approved the final version to be published.
Inciarte-Mundo et al. Arthritis Research & Therapy  (2016) 18:160 Page 8 of 10
Competing interests
The authors declare that they have no competing interests.
Ethical approval and consent to participate
This study was conducted in accordance with the Declaration of Helsinki
and was approved by the Hospital Clinic of Barcelona Clinical Research
Ethics Committee (Reg. 2013/8382). Signed informed consent was obtained
from all patients before study enrolment.
Author details
1Department of Rheumatology, Hospital Clinic, University of Barcelona, Carrer
Villarroel 170, 08036 Barcelona, Spain. 2Department of Immunology, Hospital
Clinic, University of Barcelona, Barcelona, Spain.
Received: 3 February 2016 Accepted: 23 May 2016
References
1. Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis.
Clin Pharmacol Ther. 2012;91:30–43.
2. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G,
et al. Treating rheumatoid arthritis to target: recommendations of an
international task force. Ann Rheum Dis. 2010;69:631–7.
3. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission
and active disease in rheumatoid arthritis: defining criteria for disease
activity states. Arthritis Rheum. 2005;52:2625–36.
4. Gärtner M, Alasti F, Supp G, Mandl P, Smolen JS, Aletaha D. Persistence of
subclinical sonographic joint activity in rheumatoid arthritis in sustained
clinical remission. Ann Rheum Dis. 2015;74:2050–3.
5. Anandarajah A, Thiele R, Giampoli E, Monu J, Seo GS, Feng C, et al. Patients
with rheumatoid arthritis in clinical remission manifest persistent joint
inflammation on histology and imaging studies. J Rheumatol. 2014;41:2153–60.
6. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA.
Progression of radiologic damage in patients with rheumatoid arthritis in
clinical remission. Arthritis Rheum. 2004;50:36–42.
7. Kane D, Balint PV, Sturrock RD. Ultrasonography is superior to clinical
examination in the detection and localization of knee joint effusion in
rheumatoid arthritis. J Rheumatol. 2003;30:966–71.
8. Joshua F, Edmonds J, Lassere M. Power Doppler ultrasound in musculoskeletal
disease: a systematic review. Semin Arthritis Rheum. 2006;36:99–108.
9. Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Satoh K, Tamai M, et al.
The power Doppler ultrasonography score from 24 synovial sites or 6
simplified synovial sites, including the metacarpophalangeal joints, reflects
the clinical disease activity and level of serum biomarkers in patients with
rheumatoid arthritis. Rheumatology (Oxford). 2011;50:962–5.
10. Iagnocco A, Finucci A, Ceccarelli F, Perricone C, Iorgoveanu V, Valesini G.
Power Doppler ultrasound monitoring of response to anti-tumour necrosis
factor alpha treatment in patients with rheumatoid arthritis. Rheumatology
(Oxford). 2015;54:1890–6.
11. Naredo E, Bonilla G, Gamero F, Uson J, Carmona L, Laffon A. Assessment of
inflammatory activity in rheumatoid arthritis: a comparative study of clinical
evaluation with grey scale and power Doppler ultrasonography. Ann
Rheum Dis. 2005;64:375–81.
12. Kawashiri SY, Suzuki T, Nakashima Y, Horai Y, Okada A, Iwamoto N, et al.
Ultrasonographic examination of rheumatoid arthritis patients who are free
of physical synovitis: power Doppler subclinical synovitis is associated with
bone erosion. Rheumatology (Oxford). 2014;53:562–9.
13. Wakefield RJ, Freeston JE, Hensor EM, Bryer D, Quinn MA, Emery P. Delay in
imaging versus clinical response: a rationale for prolonged treatment with
anti-tumor necrosis factor medication in early rheumatoid arthritis. Arthritis
Rheum. 2007;57:1564–7.
14. Wakefield RJ, Green MJ, Marzo-Ortega H, Conaghan PG, Gibbon WW,
McGonagle D, et al. Should oligoarthritis be reclassified? Ultrasound reveals
a high prevalence of subclinical disease. Ann Rheum Dis. 2004;63:382–5.
15. Saleem B, Brown AK, Quinn M, Karim Z, Hensor EM, Conaghan P, et al. Can
flare be predicted in DMARD treated RA patients in remission, and is it
important? A cohort study. Ann Rheum Dis. 2012;71:1316–21.
16. Hansson C, Eriksson C, Alenius GM. S-calprotectin (S100A8/S100A9): a
potential marker of inflammation in patients with psoriatic arthritis.
J Immunol Res. 2014;2014:696415.
17. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al.
Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4,
promoting lethal, endotoxin-induced shock. Nat Med. 2007;13:1042–9.
18. Berntzen HB, Olmez U, Fagerhol MK, Munthe E. The leukocyte protein L1 in
plasma and synovial fluid from patients with rheumatoid arthritis and
osteoarthritis. Scand J Rheumatol. 1991;20:74–82.
19. Hammer HB, Ødegård S, Fagerhol MK, Landewé R, van der Heijde D,
Uhlig T, et al. Calprotectin (a major leucocyte protein) is strongly and
independently correlated with joint inflammation and damage in
rheumatoid arthritis. Ann Rheum Dis. 2007;66:1093–7.
20. Hammer HB, Fagerhol MK, Wien TN, Kvien TK. The soluble biomarker
calprotectin (a S100 protein) is associated to ultrasonographic synovitis
scores and is sensitive to change in patients with rheumatoid arthritis
treated with adalimumab. Arthritis Res Ther. 2011;13:R178.
21. Hammer HB, Ødegård S, Syversen SW, Landewé R, van der Heijde D,
Uhlig T, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year
radiographic progression in patients with rheumatoid arthritis. Ann Rheum
Dis. 2010;69:150–4.
22. García-Arias M, Pascual-Salcedo D, Ramiro S, Ueberschlag ME, Jermann TM,
Cara C, et al. Calprotectin in rheumatoid arthritis: association with disease
activity in a cross-sectional and a longitudinal cohort. Mol Diagn Ther.
2013;17:49–56.
23. Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, et al.
MRP8/14 serum levels as a strong predictor of response to biological treatments
in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:499–505.
24. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems
WF, Twisk JW, et al. Development of antidrug antibodies against
adalimumab and association with disease activity and treatment failure
during long-term follow-up. JAMA. 2011;305:1460–8.
25. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al.
Development of antiinfliximab antibodies and relationship to clinical response
in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711–15.
26. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van
Riel PL, et al. Formation of antibodies against infliximab and adalimumab
strongly correlates with functional drug levels and clinical responses in
rheumatoid arthritis. Ann Rheum Dis. 2009;68:1739–45.
27. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T, RISING study. Impact of
trough serum level on radiographic and clinical response to infliximab plus
methotrexate in patients with rheumatoid arthritis: results from the RISING
study. Mod Rheumatol. 2009;19:478–87.
28. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP,
et al. Relationship between serum trough infliximab levels, pretreatment C
reactive protein levels, and clinical response to infliximab treatment in
patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64:704–7.
29. Prevoo ML, Hof MA v’t, Kuper HH, van Leeuwen MA, van de Putte LB, van
Riel PL. Modified disease activity scores that include twenty-eight-joint
counts: development and validation in a prospective longitudinal study of
patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
30. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al.
Performance of response criteria for assessing peripheral arthritis in patients
with psoriatic arthritis: analysis of data from randomised controlled trials of
two tumour necrosis factor inhibitors. Ann Rheum Dis. 2006;65:1373–8.
31. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A
simplified disease activity index for rheumatoid arthritis for use in clinical
practice. Rheumatology (Oxford). 2003;42:244–57.
32. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute
phase reactants add little to composite disease activity indices for rheumatoid
arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7:R796.
33. Backhaus M, Burmester GR, Gerber T, Grassi W, Machold KP, Swen WA, et al.
Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis.
2001;60:641–9.
34. Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, D’Agostino
MA, et al. Musculoskeletal ultrasound including definitions for
ultrasonographic pathology. J Rheumatol. 2005;32:2485–7.
35. Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen HS,
Østergaard M. Interobserver agreement in ultrasonography of the finger
and toe joints in rheumatoid arthritis. Arthritis Rheum. 2003;48:955–62.
36. Naredo E, Collado P, Cruz A, Palop MJ, Cabero F, Richi P, et al. Patients with
rheumatoid arthritis in clinical remission and ultrasound-defined active
synovitis exhibit higher disease activity and increased serum levels of
angiogenic biomarkers. Arthritis Res Ther. 2014;16:R5.
Inciarte-Mundo et al. Arthritis Research & Therapy  (2016) 18:160 Page 9 of 10
37. Ramírez J, Ruíz-Esquide V, Pomés I, Celis R, Cuervo A, Hernández MV, et al.
Longitudinal power Doppler ultrasonographic assessment of joint
inflammatory activity in early rheumatoid arthritis: predictive value in
disease activity and radiologic progression. Arthritis Rheum. 2007;57:116–24.
38. Inciarte-Mundo J, Ruiz-Esquide V, Hernández MV, Cañete JD, Cabrera-Villalba
SR, Ramirez J, et al. Calprotectin more accurately discriminates the disease
status of rheumatoid arthritis patients receiving tocilizumab than acute
phase reactants. Rheumatology (Oxford). 2015;54:2239–43.
39. Ruiz-Argüello B, del Agua AR, Torres N, Monasterio A, Martínez A, Nagore D.
Comparison study of two commercially available methods for the
determination of infliximab, adalimumab, etanercept and anti-drug
antibody levels. Clin Chem Lab Med. 2013;51:e287–9.
40. Filippucci E, Iagnocco A, Salaffi F, Cerioni A, Valesini G, Grassi W. Power
Doppler sonography monitoring of synovial perfusion at wrist joints in
patients with rheumatoid arthritis treated with adalimumab. Ann Rheum
Dis. 2006;65:1433–7.
41. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al.
Presence of significant synovitis in rheumatoid arthritis patients with
disease-modifying antirheumatic drug-induced clinical remission: evidence
from an imaging study may explain structural progression. Arthritis Rheum.
2006;54:3761–73.
42. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. An
explanation for the apparent dissociation between clinical remission and
continued structural deterioration in rheumatoid arthritis. Arthritis Rheum.
2008;58:2958–67.
43. Machado FS, Natour J, Takahashi RD, de Buosi AL, Furtado RN. Sonographic
assessment of healthy peripheral joints: evaluation according to
demographic parameters. Ultrasound Med. 2014;33:2087–98.
44. Wakefield RJ, D’Agostino MA, Naredo E, Buch MH, Iagnocco A, Terslev L,
et al. After treat-to-target: can a targeted ultrasound initiative improve RA
outcomes? Ann Rheum Dis. 2012;71:799–803.
45. Gärtner M, Mandl P, Radner H, Supp G, Machold KP, Aletaha D, et al.
Sonographic joint assessment in rheumatoid arthritis: associations with
clinical joint assessment during a state of remission. Arthritis Rheum.
2013;65:2005–14.
46. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation
of cytokines, cytokine inhibitors, and acute-phase proteins following
anti-TNF-therapy in rheumatoid arthritis. J Immunol. 1999;163:1521–8.
47. Inciarte-Mundo J, Hernández MV, Ruiz-Esquide V, Cabrera-Villalba SR,
Ramirez J, Cuervo A, et al. Serum calprotectin more accurately discriminates
the inflammatory disease activity of RA patients receiving TNF inhibitors
than acute phase reactants. Arthritis Care Res. 2015. doi:10.1002/acr.22795.
48. Hurnakova J, Zavada J, Hanova P, Hulejova H, Klein M, Mann H, et al. Serum
calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in
patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17:252.
49. Naredo E, Rodríguez M, Campos C, Rodríguez-Heredia JM, Medina JA,
Giner E, et al. Validity, reproducibility, and responsiveness of a twelve-joint
simplified power Doppler ultrasonographic assessment of joint
inflammation in rheumatoid arthritis. Arthritis Rheum. 2008;59:515–22.
50. Naredo E, Hinojosa M, Valor L, Hernández-Flórez D, Mata-Martínez C,
Serrano-Benavente B, et al. Does ultrasound-scored synovitis depend on the
pharmacokinetics of subcutaneous anti-TNF agents in patients with
rheumatoid arthritis? Rheumatology (Oxford). 2014;53:2088–94.
51. Naredo E, Wakefield RJ, Iagnocco A, Terslev L, Filippucci E, Gandjbakhch F, et al.
The OMERACT ultrasound task force—status and perspectives. J Rheumatol.
2011;38:2063–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Inciarte-Mundo et al. Arthritis Research & Therapy  (2016) 18:160 Page 10 of 10
